Latest Regulatory News

PVW Resources reports promising assay results from its Capão Bonito rare earth project and expands exploration efforts across Brazil, bolstered by new metallurgical expertise.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Euro Manganese Inc. reported a net loss of CAD 9.174 million for the half-year ending March 31, 2025, while making significant progress on its Chvaletice Manganese Project, including securing key permits and strategic status under EU and Czech frameworks. The company’s development hinges on completing a crucial private placement and share purchase plan to sustain operations.

Euro Manganese advances its Chvaletice manganese project with key regulatory approvals, leadership appointments, and a $9.8 million capital raise, while reporting a narrowed Q3 net loss.

Euro Manganese Inc. reported a $9.17 million net loss for the six months ending March 31, 2025, while advancing its Chvaletice Manganese Project and pursuing a critical $11.2 million capital raise. The company’s future hinges on successful financing and project milestones amid ongoing development costs.

EDU Holdings Limited reported a remarkable turnaround in FY24 with record revenue and profit, yet faces ongoing regulatory headwinds prompting a proposed ASX delisting. The company’s strategic pivot focuses on domestic growth and operational agility.

EDU Holdings Limited plans to voluntarily delist from the ASX, citing low share liquidity and regulatory uncertainty in the international student market. The company proposes a substantial buy-back offer to provide shareholders with an exit opportunity ahead of delisting.

Dropsuite Limited’s shares are suspended from ASX trading following Federal Court approval of its acquisition by NinjaOne Australia, marking a pivotal step in the company’s transition.

Dropsuite Limited’s acquisition by NinjaOne Australia has been legally approved, triggering a suspension of trading on the ASX and a $5.90 per share cash payout to shareholders.

Emu NL has raised $300,000 through a placement of 17.6 million shares priced at 1.7 cents each, aiming to fund its exploration projects and support working capital needs.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.